Cargando...
Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunc...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
The Korean Ophthalmological Society
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3958635/ https://ncbi.nlm.nih.gov/pubmed/24688262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3341/kjo.2014.28.2.177 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|